Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating anti-CD19 CAR-T cell therapy for refractory systemic lupus erythematosus, including lupus nephritis, and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1, Phase 2 | Status: RECRUITING